Paraneoplastic myeloneuropathies: Clinical, oncologic and serologic accompaniments
Citation Manager Formats
Make Comment
See Comments

Abstract
Objective: To test the hypothesis that myeloneuropathy is a presenting phenotype of paraneoplastic neurological syndromes, we retrospectively reviewed clinical, radiological and serological features of 32 patients with concomitant paraneoplastic spinal cord and peripheral nervous system involvements.
Methods: Observational study investigating patients with myeloneuropathy and underlying cancer and/or onconeural antibody seropositivity.
Results: Among 32 paraneoplastic myeloneuropathy patients, twenty (63%) were women with median age 61 years (range 27-84 years). Twenty-six patients (81%) had classified onconeural antibodies (amphiphysin, n=8; ANNA1 [anti-Hu] n=5; CRMP5 [anti-CV2], n=6; PCA1 [anti-Yo], n=1; PCA2, n=2; KLHL11, n=1; and combinations thereof: ANNA1/CRMP5, n=1; ANNA1/amphiphysin, n=1; ANNA3/CRMP5, n=1). Cancer was confirmed in twenty-five cases (onconeural antibodies, n=19; unclassified antibodies, n=3; no antibodies, n=3). Paraneoplastic myeloneuropathies had asymmetric paresthesias (84%), neuropathic pain (78%), subacute onset (72%) sensory ataxia (69%), bladder dysfunction (69%), and unintentional weight loss >15 pound (63%). Neurological examination demonstrated concomitant distal or asymmetric hyporeflexia and hyperreflexia (81%), impaired vibration and proprioception (69%), Babinski response (68%), and asymmetric weakness (66%). MRI showed longitudinally-extensive (45%), tract-specific spinal-cord T2-hyperintensities (39%) and lumbar nerve root enhancement (38%). Ten of twenty-eight (36%) were unable to ambulate independently at last follow-up (median: 24 months, range 5-133 months). Combined oncologic and immunologic therapy had more favorable modified Rankin scores at post-treatment follow-up compared to those receiving either oncologic or immunologic therapy alone (2 [range 1 to 4] vs 4 [range 2 to 6] p<0.001).
Conclusions: Paraneoplastic etiologies should be considered in the evaluation of subacute myeloneuropathies. Recognition of key characteristics of paraneoplastic myeloneuropathy may facilitate in early tumor diagnosis and initiation of immunosuppressive treatment.
- Received April 23, 2020.
- Accepted in final form September 21, 2020.
- Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
Disputes & Debates: Rapid online correspondence
NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within the last 8 weeks.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Related Articles
- No related articles found.